Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience

Journal for Immunotherapy of Cancer
Mohammed SalhabJames Liebmann

Abstract

Extrapulmonary small cell carcinomas (ESCC) are rare but aggressive tumors. Relapses are common despite treatment with chemotherapy and/or radiotherapy. Prospective data for treatment of ESCC are lacking; treatment of these cancers usually incorporates lung small cell carcinoma treatment recommendations. Cancer staging remains the most important prognostic factor. Cancer immunotherapy targeting the PD-1/PD-L1 pathway has shown efficacy in multiple tumor types, and could be an appealing treatment strategy for these rare tumors. We investigated PD-L1 expression by immunochemistry (IHC) in ESCCs diagnosed at University of Massachusetts Medical Center, from 1999 to 2016. 34 cases with sufficient material were selected for PD-L1 IHC analysis using clone E1L3N. PD-L1 expression was evaluated using the combined positive score (CPS). Retrospective chart review was performed. We evaluated the incidence and prognostic value of PD-L1 expression in ESCC at our institution. Twelve out 34 cases (35%) had PD-L1 CPS scores ≥1. Ten cases had CPS scores ranging 1-5, whereas 2 cases had CPS scores > 80. The overall response rate to the standard chemotherapy with/without radiotherapy in the PD-L1 positive group was 80% versus 67% for the PDL-1 neg...Continue Reading

References

Jul 3, 2004·Japanese Journal of Clinical Oncology·Jung Han KimKeunchil Park
Dec 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mary E R O'BrienTheresa Crofts
Dec 11, 2008·Cancer Treatment Reviews·Annemiek M E WalenkampDirk T Sleijfer
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 2, 2015·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·S H LimJ-M Sun
Feb 26, 2016·Virchows Archiv : an International Journal of Pathology·Marius IliePaul Hofman
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Jan 10, 2017·Frontiers in Immunology·Anja DererUdo S Gaipl
Jun 24, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick Y WenEudocia Q Lee
Aug 17, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Patrick A OttJanice M Mehnert

❮ Previous
Next ❯

Citations

Apr 23, 2019·The American Journal of Surgical Pathology·Elisheva D ShanesAnne M Mills
Aug 14, 2020·Journal of Neuro-oncology·J D PalmerD M Trifiletti
Mar 31, 2019·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Margaret MooreAnne M Mills

❮ Previous
Next ❯

Methods Mentioned

BETA
surgical resection

Clinical Trials Mentioned

NCT02054806

Software Mentioned

GraphPad Prism

Related Concepts

Related Feeds

Cancer Immunotherapy

Cancer immunotherapy is an important field of research that is looking at controlling cancer and tumor growth by activating the individuals own immune system. Recent studies have utilized chimeric antigen receptor t-cell therapy, immune checkpoint inhibitors and neoantigen vaccines. Discover the latest research on cancer immunotherapy here.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.

Related Papers

Cancer Research and Treatment : Official Journal of Korean Cancer Association
Hae Su KimMyung-Ju Ahn
Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Yuki KatsuyaKoji Tsuta
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Shintaro YokoyamaKoichi Ohshima
© 2022 Meta ULC. All rights reserved